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Abstract
Background: A high serum estradiol (E2) level is occasionally detected in postmenopausal women with common
epithelial ovarian tumors with functioning stroma. It has been proven that functioning stroma has the capacity to
convert androgens to estrogens. However, the mechanism of the initiation and development of functioning stroma
remains unclear.
Case Presentation: We present two cases of elevated E2 levels in elderly women with ovarian mucinous
adenocarcinomas that contained functioning stroma. Immunohistochemical evaluation revealed high expression levels
of aromatase and steroidogenic factor-1 (SF-1), which is considered to be a master regulator of steroidogenesis, in their
ovarian stroma.
Conclusions: These cases suggest that overexpression of SF-1 may promote estrogen biosynthesis through regulation
of P450 aromatase expression in ovarian tumors with functioning stroma; this in turn induces high serum E2 levels in
postmenopausal women with common epithelial ovarian tumors.
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Background
It is known that elevated serum levels of steroid hormones
including estradiol (E2) are present in postmenopausal
women with common epithelial ovarian tumors [1–4]. Such
ovarian tumor stroma exhibiting lutein-like or theca-like
cells, or both, is frequently detected with morphological
studies and has been termed “ovarian tumors with func-
tioning stroma” [1]. Recently, from a pathogenic perspec-
tive, it has been reported that P450 aromatase, which
converts androgens to estrogens, was exclusively expressed
in stromal cells, although not all serum estrogens are pro-
duced in functioning stroma [5]. However, the mechanism
of the initiation and development of ovarian tumors with
functioning stroma and the significance of the expression
of P450 aromatase in functioning stroma are still unclear.
We briefly describe the presence of elevated E2 levels
in postmenopausal women with ovarian mucinous adeno-
carcinoma; the tumors showed high expression levels of
aromatase and steroidogenic factor-1 (SF-1), which is a
critical regulator of reproduction that regulates the tran-
scription of key genes involved in sexual development and
reproduction [6]. Since this factor induces the differenti-
ation of mesenchymal stem cells into steroidogenic cells, it
is considered a master regulator of steroidogenesis [7].
Patients and methods
Patients
A preliminary retrospective analysis was conducted involv-
ing postmenopausal women with ovarian mucinous adeno-
carcinoma in whom serum E2 concentrations were
measured prior to undergoing gynecologic surgery because
of estrogen-related manifestations at the Department of
Obstetrics and Gynecology at Sugita Genpaku Memorial
Obama Municipal Hospital and University of Fukui from
June 2015 to September 2015. The two patients were
selected for this study because of their postmenopausal
status, defined as the absence of menses for more than
10 years in this study, and they had elevated serum E2
concentrations. The normal serum E2 concentration
after menopause is reported to be less than approximately
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20 pg/ml [8], but these two patients had ovarian mucinous
adenocarcinomas with morphologically functional stroma.
After informed consent was obtained from each patient,
for case 1, comparisons were made of the expressions of
P450 aromatase and SF-1 by immunohistochemical ana-
lysis, and for case 2, comparisons were made of expressions
of P450 aromatase and SF-1 by reverse transcription-
quantitative real-time PCR (RT-qPCR) evaluation.
Immunohistochemical analysis
All tissues were fixed in 4 % formalin and embedded in par-
affin. Standard hematoxylin and eosin (H&E)-stained sec-
tions (5μm) were made for microscopic histology
evaluation. These tissues were immunohistochemically
stained using the avidin-biotin-peroxidase complex tech-
nique with an LSAB kit (Dako, Glostrup, Denmark) [9]. Im-
munohistochemical staining was performed using primary
antibodies to the following proteins, diluted in PBS: P450
aromatase (anti-cytochrome P450 2E1 antibody ab 28146,
mouse monoclonal, 1:100, Abcam, Tokyo, Japan); and SF-1
(clone N1665, mouse monoclonal, 1:100, Perseus Proteo-
mics, Tokyo, Japan). For the staining procedure, the DAKO
Envision HRP mouse kit (Dako) with DAB as the detection
method was used. Sections from human colon and breast
cancers were used as positive controls, and, for negative
controls, incubation with the primary antibody was omitted.
RT-qPCR
We examined gene expressions of SF-1 and CYP19A1,
which encodes aromatase, in case 2 with ovarian
mucinous adenocarcinoma, as well as in KGN cells, a
tumor cell line derived from human ovarian granulosa
cells [10] and uterine leiomyosarcoma. KGN cells have
often been used as a positive control for SF-1 and
CYP19A1 expressions, and the cells have aromatase
activityto produce estrogen in the presence of its substrate
(androstenedione). Leiomyosarcoma specimens were used
as negative controls. RT-qPCR was performed as
described previously [9]. Primers used for RT-qPCR were
as follows: SF-1 (forward), 5′- CATCCTCTTCAGCC
TGGATTTG-3′ and SF-1 (reverse), 5′-CCTTCTCCTG
AGCGTCTTTCAC-3′; CYP19A1 (forward), 5′- TAGC
AGAGAAACGTGGTGAC -3′ and CYP19A1 (reverse),
5′- GAGACAGACATGGTGTCAGG -3′; ACTB (forw
ard), 5′- GGACTTCGAGCAAGAGATGG -3′ and ACTB
(reverse), 5′- AAGGAAGGCTGGAAGAGTGC -3′.
Results
Case 1: An 83-year-old woman, a retired farmer, presented
with a chief complaint of repeated postmenopausal
bleeding and an increased feeling of abdominal distension.
She had presented two years earlier with vaginal bleeding,
and endometrial cytology had shown no abnormal find-
ings. Her medical history included anxiety disorder and
hyperlipidemia. She was a non-smoker. Physical examin-
ation revealed an obese woman with abdominal fullness.
She had no palpable lymph nodes. Pelvic examination
revealed vaginal mucosa that was young for her age and a
slightly eroded vaginal fornix, with a uterus that was the
size of a hen’s egg. Her serum E2 concentration was
80 pg/ml. Ultrasound examination revealed a multilocular
cystic tumor without mural nodules. Magnetic resonance
imaging (MRI) showed a multilocular cystic mass in the
pelvis (maximum diameter approximately 20 cm). The
wall of the mass was clearly delineated, and there was no
evidence of any internal excrescences. The uterus was not
atrophic (Fig. 1a, b).
Laparotomy revealed a large left adnexal tumor with
an intact capsule. On gross examination, the tumor mea-
sured 19.0 cm x 14.0 cm x 8.5 cm. The inner surface of
the cyst was mostly smooth, with areas of irregular
thickening of the cyst wall (Fig. 1c). Microscopically, the
tumor consisted primarily of a mucinous cystadenoma
(Fig. 2a). In addition, there were 2- to 3-cell layer strati-
fications with nuclear atypia in some areas and minimal
invasion. The final pathologic diagnosis was a mucinous
adenocarcinoma. After surgery, her serum E2 level
decreased to a normal postmenopausal level.
The tumor stroma contained lutein- and theca-like cells,
so-called “ovarian tumors with functioning stroma”. The
specimen was examined immunohistochemically for SF-1
and P450 aromatase. On immunohistochemistry for SF-1,
stromal cells were immunoreactive for the enzyme, but
epithelial cells were not. SF-1-positive stromal cells
beneath the epithelial cells were somewhat aggregated
(Fig. 2b). On immunohistochemistry for P450 aromatase,
stromal cells were immunoreactive for the enzyme, but
epithelial cells were not. Aromatase-positive stromal cells
were somewhat aggregated in this tumor (Fig. 2c).
Case 2: A 59-year-old woman, an office worker, pre-
sented with a chief complaint of hematuria. She noticed
blood in her urine after she had fallen. She underwent
detailed examination at the urology department, and an
ovarian tumor was found by chance. She was referred to
our department. She had been otherwise healthy. Physical
examination revealed a slightly obese woman with abdom-
inal fullness. She had no palpable lymph nodes. On pelvic
examination, there was a whitish discharge, and the vagi-
nal mucosa was young for her age, with a slightly eroded
vaginal fornix. Ultrasonography and MRI revealed a multi-
locular cystic tumor (maximum diameter approximately
7 cm) with mural nodules in her pelvis, which highly sug-
gested malignant ovarian tumors. Her serum E2 concen-
tration was 28 pg/ml. She underwent laparotomy, and the
tumor originated from the right ovary. Histopathological
examination revealed that the tumor consisted primarily
of a mucinous adenocarcinoma with functioning stroma.
After surgery, her serum E2 level decreased to a normal
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postmenopausal level. RNA was extracted from frozen
specimens of this tumor. To assess the gene expression
levels of SF-1 and CYP19A1 in the tumor, RT-qPCR was
performed. Both SF-1 and CYP19A1 genes were expressed
in the tumor, and expression levels of these genes were
markedly higher in the tumor than in uterine leiomyosar-
coma (Fig. 3). These results suggest that SF-1 could work
as a transcriptional activator for CYP19A1, which in turn
leads to the production of estrogen in the tumor.
Case Presentation
We present two cases of elevated E2 levels in elderly
women with ovarian mucinous adenocarcinomas that
contained functioning stroma. Immunohistochemical
evaluation revealed high expression levels of aromatase
and steroidogenic factor-1 (SF-1), which is considered to
be a master regulator of steroidogenesis, in their ovarian
stroma.
Discussion
Hormonally active ovarian tumors, such as granulosa cell
tumors, thecomas, and Sertoli-Leydig cell tumors, are
classified as sex cord-stromal or steroid cell tumors. In
several reports, elevated serum levels of steroid hormones
including E2 were noted in postmenopausal women with
common epithelial ovarian tumors. Both malignant and
Fig. 1 a Sagittal T2-weighted MRI shows a multilocular cystic mass, which is clearly delineated in the pelvis (maximum diameter approximately 20 cm).
The uterus measures 80 mm in height, 55 mm in body length, and 6 mm in cavity thickness. b An ultrasound demonstrates the pelvic mass (diameter
approximately 13 cm) containing a multilocular cyst without mural nodules. c Gross appearance, the tumor measures 19.0 cm x 14.0 cm x 8.5 cm. The
inner surface of the cyst is mostly smooth, with areas of irregular thickening of the cyst wall, including yellowish mucoid substance
Fig. 2 Histopathological features of the tumor with functioning stroma (H&E; 400×). Lutein-like cells contain abundant eosinophilic cytoplasm
and round regular nuclei (a) On immunohistochemistry for SF-1 (b) and P450 aromatase (c), stromal cells are immunoreactive, but epithelial cells
are not
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benign ovarian tumors produce E2. Several studies have
reported relatively high peripheral E2 (>20 pg/ml) concen-
trations in about 50 % of postmenopausal women with
ovarian epithelial tumors, compared to the levels observed
in postmenopausal women without ovarian tumors [1–4].
Among them, the E2 released from ovarian tumors has
biological effects on bone metabolism and increases the
incidence of abnormal vaginal bleeding or abnormally
thick endometrium [8].
In these tumors, the stroma produces steroid hor-
mones, whereas the tumor cells do not. Morphologically,
such ovarian tumor stroma has lutein- and theca-like
cells (both are frequently detected), and they have been
termed “ovarian tumors with functioning stroma” [1]. In
such tumors, it has been unclear whether the tumor
stroma itself could produce estrogen. Recently, Kato et
al. reported that, on immunohistochemistry, P450 aro-
matase was exclusively expressed in the functioning stro-
mal cells showing an increase in serum E2. However,
there was no correlation between the immunoreactivity
for P450 aromatase and the serum level of E2. They con-
cluded that ovarian tumors with functioning stroma,
regardless of cell morphology, have a capacity for convert-
ing androgens (mainly of adrenal origin) to estrogens, but
this conversion usually takes place in peripheral tissues [5].
In case 1, immunoreactivity for P450 aromatase was
detected in the functioning stromal cells. In addition,
the preoperative serum level of E2 was high, and the
postoperative serum level of E2 was not detectable.
These findings may indicate a relatively high level of E2
derived from these ovarian tumors themselves. Thus, the
next question is what is the mechanism of initiation and
development of ovarian tumors with functioning stroma
through the expression of p450 aromatase.
It has been shown that CYP19A1 expression is activated
by SF-1 through its direct binding to the ovarian-specific
promoter (pII) [11]. In fact, a chromatin immunoprecipi-
tation study indicated that SF-1 bound to the pII pro-
moter in KGN cells, which are derived from human
granulosa cell tumors [12]. Furthermore, in the study of
Pelusi et al. using SF-1 knockout (KO) mice, KO mice
with markedly decreased SF-1 expression in granulosa
cells, they found that these KO mice had hypoplastic ovar-
ies that contained a decreased number of follicles and
lacked corpora lutea. Moreover, they had blunted induc-
tion of plasma estradiol in response to gonadotropins, and
they had reduced ovarian expression of anti-mullerian
hormone, as well as decreased gonadotropin-induced
ovarian expression of aromatase and cyclin D2 [13]. Thus,
SF-1 is considered to be a master regulator of steroidogen-
esis, and it promotes estrogen biosynthesis through the
regulation of P450 aromatase gene promoter PII in the
ovarian follicle [14]. Recently, Miller et al. reported that
the SF-1 gene exhibits frequent genetic (LOH/base sub-
stitution) and epigenetic (methylation) alterations in
ovarian tumors [15]. Hu et al. conducted a meta-
analysis that suggested that SF-1 may play an important
role in ovarian cancer initiation and progression. In
addition, they noted that SF-1 protein expression is not
significantly different between benign and malignant
ovarian tumors. SF-1 is also expressed in stromal cells
and promotes angiogenesis [16]. Recently, Ferraz-de-
Souza et al. reported angiopoietin 2 as a novel target of
SF-1. This indicated a potential for the development of
a new ovarian cancer treatment through SF-1 inducing
angiogenesis [17].
In case 1, immunoreactivity for SF-1 was detected in
the functioning stromal cells, which almost accorded
with p450 aromatase expression, although there was
some difference in intensity between p450 aromatase
expression and SF-1 expression. In case 2, assessing the
gene expression levels for SF-1 and CYP19A1 in the
Fig. 3 Expression levels of SF-1 (a) and CYP19A1 (b) in KGN cells, a tumor cell line derived from human ovarian granulosa cells, a mucinous
adenocarcinoma (M), and a uterine leiomyosarcoma (ULMS). Six pieces were randomly collected from each specimen. The gene expressions of SF-1
and CYP19A1 were measured by quantitative real-time PCR. The mRNA levels were normalized against ACTB. Data are the means ± SEM (n = 6). ND,
Not detected
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tumor by RT-qPCR showed that they were consistent
with the results of immunohistochemical studies; both
SF-1 and CYP19A1 genes were expressed in the tumor.
Based on these facts, it is reasonable to suggest that the
overexpression of SF-1 may promote estrogen biosyn-
thesis through regulation of P450 aromatase expression
in ovarian tumors with functioning stroma, and this in
turn induces a high serum E2 level.
In addition, the E2 released from these ovarian mucin-
ous adenocarcinomas has biological effects on the
enlarged uterus and the incidence of abnormal vaginal
bleeding or abnormally thick endometrium. The study of
the radioanatomy of the uterus on MRI has indicated
that the normal post-menopausal uterus has a relatively
high intensity signal on T1 and T2-weighted sequences,
close to that of fatty tissue. It also indicated that the size
of the uterus (uterine height, uterine body length, and
uterine cavity thickness) was significantly smaller than
that of the premenopausal uterus. The threshold values
to classify the uterine height, uterine body length, and
uterine cavity thickness as normal on sagittal T2-
weighted images were < 70 mm, < 50 mm, and <1 mm,
respectively, for postmenopausal women [18, 19]. Based
on these facts, the size of the uterus of Case 1 was
clearly larger than that of a normal postmenopausal
uterus.
There is strong in vitro and in vivo evidence that
estrogens (and potentially other steroids) regulate ovarian
carcinogenesis [20]. Furthermore, there has been increasing
epidemiologic data, which come from individual participant
datasets from 52 epidemiological studies involved in
prospective studies (with last hormone therapy use
extrapolated forwards for up to 4 years) in postmeno-
pausal women. A meta-analysis showed that ovarian
cancer risk was significantly greater in ever-users than
in never-users of hormone therapy. However, regarding
histopathological type, risk was definitely increased
only for the two most common types, serous and endo-
metrioid, but not mucinous and clear adenocarcinoma
[21]. Sie at al. examined whether tumor expressions of
the progesterone receptor (PR) and estrogen receptor
(ER) were associated with subtype-specific survival.
They found that PR and ER are prognostic biomarkers
for only endometrioid and high-grade serous ovarian
cancers, not for mucinous ovarian cancer [22]. This
may be one of the reasons why serum estrogen levels in
postmenopausal women have not been linked to biological
behavior for ovarian mucinous adenocarcinoma. Chen et
al. investigated the influence of sex hormone levels on
tumor biology and patients’ outcomes in ovarian cancer.
They concluded that there is no clear evidence of a prog-
nosis marker or progression of elevated serum estradiol
levels for common epithelial ovarian cancer including
mucinous ovarian cancer [23]. Based on these findings,
serum estrogen levels in postmenopausal women are not
linked to the biological behavior of ovarian mucinous
adenocarcinoma. Steroid hormone signaling in ovarian
cancer is complex, yet little understood. Further investiga-
tions are needed.
Conclusions
The present case showed that some elderly women with
common epithelial tumors have an extremely high E2
level. Immunohistochemical and RT-qPCR evaluations
showed that SF-1 may promote estrogen biosynthesis
through regulation of P450 aromatase expression in
ovarian tumors with functioning stroma, and that this in
turn induces a high serum E2 level.
Further large-scale studies should provide additional
insights into the mechanism whereby ovarian tumors,
which contain functioning stroma with a high serum
estrogen level and high expressions of P450 aromatase
and SF-1, affect the prognosis and clinical outcomes of
ovarian tumor patients. These studies have the potential
to identify new biomarkers for anti-angiogenetic therapy
and new treatments for some ovarian tumors.
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